Novartis initiates trial for Votoplam in Huntington's Disease patients
Novartis is conducting a study to evaluate the efficacy, safety, and tolerability of Votoplam in early symptomatic Huntington's Disease patients.
Indication
Clinical and regulatory intelligence for Huntington's Disease with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.